Novo Nordisk has announced a lawsuit against rival Eli Lilly, alleging that the latter has engaged in misleading and false advertising concerning their GLP-1 weight-loss drugs. The lawsuit highlights the intense competition between these pharmaceutical giants in the obesity treatment market, with Novo accusing Eli Lilly of running a pattern of deceptive advertising in its campaigns for drugs like Zepbound and Mounjaro. Eli Lilly has asserted that its advertisements are truthful and plans to defend against the lawsuit vigorously. This legal battle underscores the escalating tensions in the weight-loss drug sector.